238 related articles for article (PubMed ID: 20920984)
1. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer.
Munzone E; Nolé F; Goldhirsch A; Botteri E; Esposito A; Zorzino L; Curigliano G; Minchella I; Adamoli L; Cassatella MC; Casadio C; Sandri MT
Clin Breast Cancer; 2010 Oct; 10(5):392-7. PubMed ID: 20920984
[TBL] [Abstract][Full Text] [Related]
2. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.
Fehm T; Müller V; Aktas B; Janni W; Schneeweiss A; Stickeler E; Lattrich C; Löhberg CR; Solomayer E; Rack B; Riethdorf S; Klein C; Schindlbeck C; Brocker K; Kasimir-Bauer S; Wallwiener D; Pantel K
Breast Cancer Res Treat; 2010 Nov; 124(2):403-12. PubMed ID: 20859679
[TBL] [Abstract][Full Text] [Related]
3. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.
Pestrin M; Bessi S; Galardi F; Truglia M; Biggeri A; Biagioni C; Cappadona S; Biganzoli L; Giannini A; Di Leo A
Breast Cancer Res Treat; 2009 Dec; 118(3):523-30. PubMed ID: 19597704
[TBL] [Abstract][Full Text] [Related]
4. Quantitative determination of HER2 expression by confocal microscopy assay in CTCs of breast cancer.
Cao S; Li Y; Li J; Li CF; Zhang W; Yang ZQ; Meng SD
Oncol Rep; 2010 Feb; 23(2):423-8. PubMed ID: 20043103
[TBL] [Abstract][Full Text] [Related]
5. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients.
Wülfing P; Borchard J; Buerger H; Heidl S; Zänker KS; Kiesel L; Brandt B
Clin Cancer Res; 2006 Mar; 12(6):1715-20. PubMed ID: 16551854
[TBL] [Abstract][Full Text] [Related]
6. Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study.
Stojadinovic A; Mittendorf EA; Holmes JP; Amin A; Hueman MT; Ponniah S; Peoples GE
Ann Surg Oncol; 2007 Dec; 14(12):3359-68. PubMed ID: 17906897
[TBL] [Abstract][Full Text] [Related]
7. Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients.
Giordano A; Giuliano M; De Laurentiis M; Eleuteri A; Iorio F; Tagliaferri R; Hortobagyi GN; Pusztai L; De Placido S; Hess K; Cristofanilli M; Reuben JM
Breast Cancer Res Treat; 2011 Sep; 129(2):451-8. PubMed ID: 21710134
[TBL] [Abstract][Full Text] [Related]
8. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study.
Rink M; Chun FK; Dahlem R; Soave A; Minner S; Hansen J; Stoupiec M; Coith C; Kluth LA; Ahyai SA; Friedrich MG; Shariat SF; Fisch M; Pantel K; Riethdorf S
Eur Urol; 2012 Apr; 61(4):810-7. PubMed ID: 22277196
[TBL] [Abstract][Full Text] [Related]
9. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
[TBL] [Abstract][Full Text] [Related]
10. Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status.
Souglakos J; Vamvakas L; Apostolaki S; Perraki M; Saridaki Z; Kazakou I; Pallis A; Kouroussis C; Androulakis N; Kalbakis K; Millaki G; Mavroudis D; Georgoulias V
Breast Cancer Res; 2006; 8(4):R36. PubMed ID: 16846533
[TBL] [Abstract][Full Text] [Related]
11. Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance.
Apostolaki S; Perraki M; Kallergi G; Kafousi M; Papadopoulos S; Kotsakis A; Pallis A; Xenidis N; Kalmanti L; Kalbakis K; Agelaki S; Kalykaki A; Stournaras C; Stathopoulos E; Georgoulias V; Mavroudis D
Breast Cancer Res Treat; 2009 Oct; 117(3):525-34. PubMed ID: 19016323
[TBL] [Abstract][Full Text] [Related]
12. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor.
Beije N; Onstenk W; Kraan J; Sieuwerts AM; Hamberg P; Dirix LY; Brouwer A; de Jongh FE; Jager A; Seynaeve CM; Van NM; Foekens JA; Martens JW; Sleijfer S
Neoplasia; 2016 Nov; 18(11):647-653. PubMed ID: 27764697
[TBL] [Abstract][Full Text] [Related]
14. Detection of circulating tumor cells in peripheral blood of heavily treated metastatic breast cancer patients.
Tokudome N; Ito Y; Takahashi S; Kobayashi K; Taira S; Tsutsumi C; Oto M; Oba M; Inoue K; Kuwayama A; Masumura K; Nakayama Y; Watanabe C; Hatake K
Breast Cancer; 2011 Jul; 18(3):195-202. PubMed ID: 21465230
[TBL] [Abstract][Full Text] [Related]
15. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients.
Zhang S; Li L; Wang T; Bian L; Hu H; Xu C; Liu B; Liu Y; Cristofanilli M; Jiang Z
BMC Cancer; 2016 Jul; 16():526. PubMed ID: 27456503
[TBL] [Abstract][Full Text] [Related]
16. Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer.
Nakamura S; Yagata H; Ohno S; Yamaguchi H; Iwata H; Tsunoda N; Ito Y; Tokudome N; Toi M; Kuroi K; Suzuki E
Breast Cancer; 2010 Jul; 17(3):199-204. PubMed ID: 19649686
[TBL] [Abstract][Full Text] [Related]
17. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.
Wallwiener M; Hartkopf AD; Baccelli I; Riethdorf S; Schott S; Pantel K; Marmé F; Sohn C; Trumpp A; Rack B; Aktas B; Solomayer EF; Müller V; Janni W; Schneeweiss A; Fehm TN
Breast Cancer Res Treat; 2013 Jan; 137(2):503-10. PubMed ID: 23271327
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
[TBL] [Abstract][Full Text] [Related]
19. Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients.
Kallergi G; Agelaki S; Papadaki MA; Nasias D; Matikas A; Mavroudis D; Georgoulias V
Breast Cancer Res; 2015 Aug; 17(1):113. PubMed ID: 26285572
[TBL] [Abstract][Full Text] [Related]
20. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients.
Sieuwerts AM; Mostert B; Bolt-de Vries J; Peeters D; de Jongh FE; Stouthard JM; Dirix LY; van Dam PA; Van Galen A; de Weerd V; Kraan J; van der Spoel P; Ramírez-Moreno R; van Deurzen CH; Smid M; Yu JX; Jiang J; Wang Y; Gratama JW; Sleijfer S; Foekens JA; Martens JW
Clin Cancer Res; 2011 Jun; 17(11):3600-18. PubMed ID: 21505063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
